Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hellström, I.
Right arrow Articles by Hellström, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hellström, I.
Right arrow Articles by Hellström, K. E.
[Cancer Research 61, 2420-2423, March 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Overexpression of HER-2 in Ovarian Carcinomas1

Ingegerd Hellström2, Gary Goodman, Janice Pullman, Yi Yang and Karl Erik Hellström

Program in Tumor Immunology, Pacific Northwest Research Institute [I. H., J. P., Y. Y., K. E. H.], and Swedish Hospital and Medical Center, Tumor Institute [G. G.], Seattle, Washington 98122

The transmembrane receptor encoded by the HER-2 cellular oncogene is amplified in several types of human carcinomas and provides an attractive therapeutic target. Shown by immunohistology, <25% of newly diagnosed ovarian carcinomas express the HER-2 protein. However, now we report that this protein was expressed in all 20 tumor cell lines derived from stage III and IV ovarian cancers as well as in tumor cells harvested from patients with malignant ascites and in tumor samples taken at a second surgery, suggesting that cells with excess expression may have a selective growth advantage. HER-2-positive ovarian carcinoma cells were shown to be sensitive to antibody-dependent cellular cytotoxicity, and their in vitro proliferation was inhibited by anti-HER-2 MAb Herceptin. We postulate, therefore, that therapy which targets HER-2 may be more efficacious in patients with ovarian carcinoma than indicated by the commonly low expression of HER-2 in tumors removed at the time of primary surgery.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Carlsten, H. Norell, Y. T. Bryceson, I. Poschke, K. Schedvins, H.-G. Ljunggren, R. Kiessling, and K.-J. Malmberg
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
J. Immunol., October 15, 2009; 183(8): 4921 - 4930.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Reim, Y. Dombrowski, C. Ritter, M. Buttmann, S. Hausler, M. Ossadnik, M. Krockenberger, D. Beier, C. P. Beier, J. Dietl, et al.
Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells
Cancer Res., October 15, 2009; 69(20): 8058 - 8066.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. W. Warrenfeltz, S. A. Lott, T. M. Palmer, J. C. Gray, and D. Puett
Luteinizing Hormone-Induced Up-Regulation of ErbB-2 Is Insufficient Stimulant of Growth and Invasion in Ovarian Cancer Cells
Mol. Cancer Res., November 1, 2008; 6(11): 1775 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Quaye, S. A. Gayther, S. J. Ramus, R. A. Di Cioccio, V. McGuire, E. Hogdall, C. Hogdall, J. Blaakr, D. F. Easton, B. A.J. Ponder, et al.
The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival
Clin. Cancer Res., September 15, 2008; 14(18): 5833 - 5839.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L-L. Chiang, J. A. Ledermann, E. Aitkens, E. Benjamin, D. R. Katz, and B. M. Chain
Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor
Clin. Cancer Res., August 1, 2008; 14(15): 4898 - 4907.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Katsumi, Y. Kuwahara, S. Tamura, K. Kikuchi, O. Otabe, K. Tsuchiya, T. Iehara, H. Kuroda, H. Hosoi, and T. Sugimoto
Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Clin. Cancer Res., February 15, 2008; 14(4): 1192 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al.
Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity.
Cancer Res., June 15, 2006; 66(12): 6387 - 6394.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
I. Hellstrom, J. Raycraft, S. Kanan, N. Y. Sardesai, T. Verch, Y. Yang, and K. E. Hellstrom
Mesothelin variant 1 is released from tumor cells as a diagnostic marker.
Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1014 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
R. J. Pietras and O. K. Weinberg
Antiangiogenic Steroids in Human Cancer Therapy
Evid. Based Complement. Altern. Med., March 1, 2005; 2(1): 49 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Madhusudan, A. Tamir, N. Bates, E. Flanagan, M. E. Gore, D. P. J. Barton, P. Harper, M. Seckl, H. Thomas, N. R. Lemoine, et al.
A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene
Clin. Cancer Res., May 1, 2004; 10(9): 2986 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
B. S. Goueli and R. Janknecht
Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf
Mol. Cell. Biol., January 1, 2004; 24(1): 25 - 35.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. C. Dowdy, A. Mariani, and R. Janknecht
HER2/Neu- and TAK1-mediated Up-regulation of the Transforming Growth Factor {beta} Inhibitor Smad7 via the ETS Protein ER81
J. Biol. Chem., November 7, 2003; 278(45): 44377 - 44384.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J. A. Ledbetter, M. Schummer, M. McIntosh, C. Drescher, N. Urban, and K. E. Hellstrom
The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma
Cancer Res., July 1, 2003; 63(13): 3695 - 3700.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. Navo and J. A. Smith
Update on the Prevention and Treatment of Ovarian Cancer
Journal of Pharmacy Practice, June 1, 2003; 16(3): 149 - 156.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, J. Agha, J. J. Roman, L. Hutchins, S. Pecorelli, T. O'Brien, et al.
Overexpression of HER-2/Neu in Uterine Serous Papillary Cancer
Clin. Cancer Res., May 1, 2002; 8(5): 1271 - 1279.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.